Jack Wallace
Stock Analyst at Guggenheim
(2.71)
# 1,812
Out of 4,820 analysts
22
Total ratings
52.63%
Success rate
3.83%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $227.54 | +9.43% | 4 | Oct 1, 2024 | |
| WW WW International | Maintains: Buy | $12 → $6 | $0.40 | +1,416.68% | 3 | Aug 2, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $28.09 | -39.48% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $4.10 | +241.46% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $150.34 | +46.33% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $24.75 | +61.62% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $7.73 | +1,193.66% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $20.06 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $227.54
Upside: +9.43%
WW International
Aug 2, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $0.40
Upside: +1,416.68%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $28.09
Upside: -39.48%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $4.10
Upside: +241.46%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $150.34
Upside: +46.33%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $24.75
Upside: +61.62%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $7.73
Upside: +1,193.66%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $20.06
Upside: -